当大多数人仍聚焦于让机器人承担端茶倒水等家务时，来自瑞士联邦理工学院（洛桑， EPFL ）、美国杜克大学与葡萄牙高等理工大学的联合团队，已率先 运用机器人部分替代动物开展生理学实验 ，旨在深入探究动物神经网络对各类智能行为的调控机制。 他们的最新研究成果 —— 题为《机器鱼连续与间歇游泳的能效与神经控制（ Energy Efficiency and Neural Control of Continuous versus Intermittent Swimming in a Fish-like Robot ）》的论文，已发表于顶刊《科学・机器人（ Science Robotics ）》 2026 年 1 月号（图 1 ）。 论文标题： Energy Efficiency and Neural Control of Continuous versus Intermittent Swimming in a Fish-like Robot. 值得注意的是，去年 10 月，该团队另一项通过机器鱼仿真研究斑马鱼视觉运动反应（ optomotor response ）的成果《人工具身神经网络揭示脊椎动物视 觉运动行为的神经 ...

Core Viewpoint - Zhaoyan New Drug (603127) has seen a significant stock price increase of 9.23%, reaching HKD 24.62, with a trading volume of HKD 391 million, indicating positive market sentiment towards the company [1] Company Analysis - Huatai Securities reports that after experiencing high growth from 2018 to 2022, Zhaoyan New Drug is expected to face order volume and price pressures from 2023 to 2025, but these negative factors are gradually being resolved. Starting in 2026, the company is anticipated to enter a new growth phase driven by domestic recovery and offshore outsourcing [1] - The price of experimental monkeys, a key indicator of supply and demand in the safety evaluation industry, is currently stable at RMB 80,000 to 100,000 per monkey, with a slight upward trend expected as supply-demand dynamics tighten [1] - The report suggests that as the supply-demand gap widens, monkey prices may enter a new upward cycle, having previously reached RMB 150,000 to 200,000 per monkey in 2022 [1] Industry Outlook - Contrary to market concerns regarding the impact of new FDA regulations and the growth potential of overseas business, Huatai Securities believes that the new regulations are primarily focused on the monoclonal antibody sector and have not yet been adopted domestically. In the short term, animal testing will remain the dominant method in global drug safety evaluation for the next 3 to 5 years [1] - Long-term prospects for new methodologies, such as AI and organoids, remain uncertain and will require careful evaluation of transitional results and technological maturity [1] - The report expresses optimism about the collaborative evolution of animal testing and new methodologies, which could drive overall industry development, and highlights the company's proactive positioning in adopting new methodologies to enhance its comprehensive capabilities [1]